α-Galactosidase activity should be examined in patients with proteinuria: What have we learned from a family affected with Fabry disease? [5]

Nephrology Dialysis Transplantation

Volumn 21, Issue 2, 2006, Pages 549-550

  Lee, Ni Chung ^a   Niu, Dau Ming ^a,b   Lin, Ching Yuang ^c,d   Hsiao, Kwang Jen ^a   Yang, An Hang ^a   Ng, Yee Yung ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; CASE REPORT; CLINICAL FEATURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DISEASE EXACERBATION; EARLY DIAGNOSIS; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; FAMILY HISTORY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FUNCTION; LETTER; MALE; PRIORITY JOURNAL; PROTEINURIA;

ADULT; ALPHA-GALACTOSIDASE; FABRY DISEASE; HUMANS; KIDNEY DISEASES; MALE; PROTEINURIA;

EID: 31544437690     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi191     Document Type: Letter

References (4)

1. Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 2002; 13 [Suppl 2]: S139-S143
2. Wilcox WR, Banikazemi M, Guffon N et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75: 65-74
3. del Toro N, Milan JA, Palma A. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return? Nephrol Dial Transplant 2004; 19: 1018
4. Nakao S, Kodama C, Takenaka T et al. Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003; 64: 801-807